 |
16 Diseases |  |
0 Trials |
|
0 Trials |  |
44 News |  |
- deferitazole (SHP602) / Takeda
Trial initiation date, Trial primary completion date, MRI: Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - May 7, 2015
P2, N=0, Withdrawn, Sponsor: Shire
Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Oct 2014 --> Jul 2014
- deferitazole (SHP602) / Takeda
Trial primary completion date, MRI: Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - May 6, 2015
P2, N=0, Withdrawn, Sponsor: Shire
Initiation date: Oct 2014 --> Jul 2014 | Trial primary completion date: Oct 2014 --> Jul 2014 Trial primary completion date: Oct 2015 --> Oct 2014
- deferitazole (SHP602) / Takeda
Trial termination, Trial primary completion date: Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload (clinicaltrials.gov) - Aug 8, 2014
P2, N=30, Terminated, Sponsor: Shire
Suspended --> Terminated | Trial primary completion date: Feb 2015 --> Jul 2014; This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
- deferitazole (SHP602) / Takeda
Enrollment change, Trial withdrawal: Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt) (clinicaltrials.gov) - Aug 8, 2014
P1, N=0, Withdrawn, Sponsor: Shire
Evaluation of nonclinical rat findings is ongoing. N=30 --> 0 | Suspended --> Withdrawn
- deferitazole (SHP602) / Takeda
Enrollment change, Trial withdrawal, MRI: Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - Aug 8, 2014
P2, N=0, Withdrawn, Sponsor: Shire
N=30 --> 0 | Suspended --> Withdrawn N=50 --> 0 | Suspended --> Withdrawn
- deferitazole (SHP602) / Takeda
Enrollment change, Trial termination, Trial primary completion date: Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184) (clinicaltrials.gov) - Aug 8, 2014
P2, N=30, Terminated, Sponsor: Shire
N=1500 --> 30 | Suspended --> Terminated | Trial primary completion date: May 2023 --> Jul 2014; This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
- deferitazole (SHP602) / Takeda
Enrollment change, Trial termination: Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - Aug 8, 2014
P2, N=32, Terminated, Sponsor: Shire
N=50 --> 32 | Suspended --> Terminated; This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
- deferitazole (SHP602) / Takeda
Trial suspension: Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt) (clinicaltrials.gov) - Mar 17, 2014
P1, N=30, Suspended, Sponsor: Shire
Evaluation of nonclinical rat findings is ongoing. Not yet recruiting --> Suspended
- deferitazole (SHP602) / Takeda
Trial suspension, MRI: Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - Mar 17, 2014
P2, N=50, Suspended, Sponsor: Shire
Not yet recruiting --> Suspended Not yet recruiting --> Suspended
- | deferitazole (SHP602) / Takeda
Trial suspension: Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184) (clinicaltrials.gov) - Mar 17, 2014
P2, N=1500, Suspended, Sponsor: Shire
Not yet recruiting --> Suspended Enrolling by invitation --> Suspended
- deferitazole (SHP602) / Takeda
Trial suspension: Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - Mar 17, 2014
P2, N=50, Suspended, Sponsor: Shire
Enrolling by invitation --> Suspended Recruiting --> Suspended
- deferitazole (SHP602) / Takeda
Trial suspension: Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload (clinicaltrials.gov) - Mar 17, 2014
P2, N=30, Suspended, Sponsor: Shire
Recruiting --> Suspended Recruiting --> Suspended
- deferitazole (SHP602) / Takeda
Trial initiation date, MRI: Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - Mar 17, 2014
P2, N=50, Suspended, Sponsor: Shire
Recruiting --> Suspended Initiation date: Apr 2014 --> Nov 2014
- deferitazole (SHP602) / Takeda
New P1 trial: Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt) (clinicaltrials.gov) - Feb 17, 2014
P1, N=30, Suspended, Sponsor: Shire
- deferitazole (SHP602) / Takeda
Trial completion: Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects (clinicaltrials.gov) - Jan 7, 2014
P1, N=30, Completed, Sponsor: Shire Development LLC
Initiation date: Apr 2014 --> Nov 2014 Recruiting --> Completed
- deferitazole (SHP602) / Takeda
Trial completion: Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects (clinicaltrials.gov) - Jan 7, 2014
P1, N=30, Completed, Sponsor: Shire Development LLC
Recruiting --> Completed Recruiting --> Completed
- deferitazole (SHP602) / Takeda
New P1 trial: Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects (clinicaltrials.gov) - Nov 18, 2013
P1, N=30, Completed, Sponsor: Shire Development LLC
- deferitazole (SHP602) / Takeda
New P1 trial: Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects (clinicaltrials.gov) - Nov 6, 2013
P1, N=30, Completed, Sponsor: Shire Development LLC
- deferitazole (SHP602) / Takeda
Trial completion: The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects (clinicaltrials.gov) - Oct 3, 2013
P1, N=9, Completed, Sponsor: Shire Development LLC
Recruiting --> Completed Not yet recruiting --> Completed
- deferitazole (SHP602) / Takeda
Trial completion: A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt) (clinicaltrials.gov) - Oct 3, 2013
P1, N=24, Completed, Sponsor: Shire Development LLC
Not yet recruiting --> Completed Active, not recruiting --> Completed
- deferitazole (SHP602) / Takeda
New P2 trial, MRI: Treatment of Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - Aug 21, 2013
P2, N=50, Suspended, Sponsor: Shire
- deferitazole (SHP602) / Takeda
New P1 trial: The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects (clinicaltrials.gov) - Jul 21, 2013
P1, N=9, Completed, Sponsor: Shire Development LLC
- deferitazole (SHP602) / Takeda
New P1 trial: A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt) (clinicaltrials.gov) - Jul 21, 2013
P1, N=24, Completed, Sponsor: Shire Development LLC
- deferitazole (SHP602) / Takeda
Trial completion: AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184 (clinicaltrials.gov) - Jun 30, 2013
P1, N=6, Completed, Sponsor: Shire Development LLC
Active, not recruiting --> Completed Recruiting --> Completed
- deferitazole (SHP602) / Takeda
Trial initiation date: Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - May 2, 2013
P2, N=50, Suspended, Sponsor: Shire
Recruiting --> Completed Initiation date: Jun 2012 --> Sep 2012
- deferitazole (SHP602) / Takeda
Trial completion: Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function (clinicaltrials.gov) - May 2, 2013
P1, N=44, Completed, Sponsor: Shire Development LLC
Initiation date: Jun 2012 --> Sep 2012 Recruiting --> Completed
- deferitazole (SHP602) / Takeda
Trial completion: Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function (clinicaltrials.gov) - Apr 16, 2013
P1, N=66, Completed, Sponsor: Shire Development LLC
Recruiting --> Completed Active, not recruiting --> Completed
- deferitazole (SHP602) / Takeda
New P1 trial: AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184 (clinicaltrials.gov) - Apr 2, 2013
P1, N=6, Completed, Sponsor: Shire Development LLC
- deferitazole (SHP602) / Takeda
Enrollment change: Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload (clinicaltrials.gov) - Jan 21, 2013
P2, N=51, Completed, Sponsor: Shire Development LLC
Active, not recruiting --> Completed N=34 --> 51
- deferitazole (SHP602) / Takeda
Trial completion: Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload (clinicaltrials.gov) - Jan 21, 2013
P2, N=51, Completed, Sponsor: Shire Development LLC
N=34 --> 51 Active, not recruiting --> Completed
- deferitazole (SHP602) / Takeda
New P1 trial: Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function (clinicaltrials.gov) - Nov 20, 2012
P1, N=44, Completed, Sponsor: Shire Development LLC
- deferitazole (SHP602) / Takeda
New P1 trial: Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function (clinicaltrials.gov) - Oct 25, 2012
P1, N=66, Completed, Sponsor: Shire Development LLC
- | deferitazole (SHP602) / Takeda
New P2 trial: Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184) (clinicaltrials.gov) - Aug 21, 2012
P2, N=1500, Suspended, Sponsor: Shire
- deferitazole (SHP602) / Takeda
New P2 trial: Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy (clinicaltrials.gov) - May 22, 2012
P2, N=50, Suspended, Sponsor: Shire
- Ibsrela (tenapanor) / Ardelyx, deferitazole (SHP602) / Takeda
New P2 trial: Study to evaluate FBS0701 in a pediatric population with transfusioanl iron overload Studio per la valutazione di FBS0701 in una popolazione pediatrica affetta da sovraccarico di ferro di origine trasfusionale (EUDRACT) - Mar 19, 2012
P2, N=0, Ongoing, Sponsor: FERROKIN BIOSCIENCES INC.
- Ibsrela (tenapanor) / Ardelyx, Kyowa Kirin, Knight Therap, deferitazole (SHP602) / Takeda
Enrollment change: Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload (clinicaltrials.gov) - Feb 7, 2012
P1b, N=20, Completed, Sponsor: FerroKin BioSciences, Inc.
Active, not recruiting --> Completed N=16 --> 20